Afuco™ Anti-Human CLDN6 ADCC Therapeutic Antibody (IMAB 027), ADCC Enhanced
Anti-CLDN6 ADCC Enhanced Antibody (IMAB 027) is an ADCC enhanced antibody produced by our Afuco™ platform. IMAB027 is a first-in-class monoclonal antibody selectively binding to the cell surface protein Claudin-6 (CLDN6) which is present in a wide range of cancers, including testicular, ovarian, uterine, and lung cancers. A key advantage of IMAB027 is that CLDN6 is an embryonic antigen which is absent from healthy adult tissue. This unmatched tumor cell specificity of CLDN6 makes IMAB027 a cancer cell selective drug allowing it to efficiently kill tumor cells without harming healthy non-cancerous cells.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-160CL |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | CLDN6 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4 °C, -20°C if preferred |